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Abstract SNAP-25, a synaptosomal ssociated membrane pro- 
tein of 25 kDa, participates in the presynaptic process of vesicle- 
plasma membrane fusion that results in neurotransmitter release 
at central nervous system synapses. SNAP-25 occurs in neuroen- 
docrine cells and, in analogy to its role in neurons, has been 
implicated in catecholamine secretion, yet the nature of the under- 
lying mechanism remains obscure. Here we use an anti-SNAP-25 
monoclonal antibody to show that SNAP-25 is localized at the 
cytosolic surface of the plasma membrane of chromaffin cells. 
This antibody inhibited the Ca2+-evoked eatecholamine release 
from digitonin-permeabilized chromaffin cells in a time- and dose- 
dependent manner. Remarkably, a 20-met synthetic peptide rep- 
resenting the sequence of the C-terminal domain of SNAP-25 
blocked CaZ+-dependent catecholamine r lease with an ICso = 20 
/tM. The inhibitory activity of the peptide was sequence-specific 
as evidenced by the inertness of a control peptide with the same 
amino acid composition but random order. The C-terminal seg- 
ment of SNAP-25, therefore, plays a key role in regulating Ca 2+- 
dependent exocytosis, presumably mediated via interactions with 
other protein components of the fusion complex. 
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1. Introduction 
Increasing evidence demonstrates the presence of common 
protein constituents on the exocytotic machinery in neuronal 
and neuroendocrine cells [1]. Membrane fusion is preceded by 
the docking and priming of neurotransmitter containing vesi- 
cles at active sites forming a multi-protein fusion complex [2 5]. 
This complex involves vesicle components such as synapto- 
brevin [6,7] and plasmalemma proteins as SNAP-25 and syn- 
taxin [8]. SNAP-25, a neuronal-specific protein, is anchored to 
the plasma membrane via cysteine palmitoylation [9], and inter- 
acts with both synaptobrevin a d syntaxin through its carboxy 
and amino-terminal domains, respectively [10,11]. 
Poignant evidence implicating these components in neuro- 
transmision emerged from the action of clostridial tetanus and 
botulinum neurotoxins that block secretion by cleaving synap- 
tobrevin, syntaxin and SNAP-25 [12-14]. The participation of
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SNAP-25 in synaptic vesicular trafficking and fusion was in- 
ferred from the structural similarity with the yeast SEC9 gene 
product, required for the fusion of Golgi-derived secretory ves- 
icles with plasma membranes [15], and from the finding that 
antisense oligonucleotides inhibit axonal growth [16]. 
Significant expression of SNAP-25 is detected in neuroendo- 
crine cells such as chromaffin cells [17,18], yet its role in Ca 2+- 
dependent secretion isnot well understood. Here, we show that 
SNAP-25 and specifically its carboxy-terminal domain regu- 
lates Ca2+-dependent xocytosis in chromaffin cells. 
2. Materials and methods 
2,1. Reagents 
Monoclonal anti-SNAP-25 antibody was from Sternberger Mono- 
clonals Inc. (Baltimore, MD); rhodamine-conjugated rabbit anti-mouse 
lgG and mouse IgG were from Sigma (St. Louis, MO); [3H]Noradrenal- 
ine was from DuPont; t-Boc and Fmoc amino acids, with standard side 
chain protecting roups, were from Applied Biosystems (Foster City, 
CA), NovaBio-Chem (La Jolla, CA) or Peninsula Laboratories 
(Belmont, CA). Solvents, reagents and resins for peptide synthesis were 
from Applied Biosystems. All other eagents were of analytical grade 
from Sigma. 
2.2. Chromaffin cell cultures 
Chromaffin cells were prepared from bovine adrenal glands by col- 
lagenase digestion and further separated from debris and erythrocytes 
by centrifugation  Percoll gradients [19]. Cells were maintained in
monolayer cultures at a density of 500,000 cells/cm 2 and used between 
the third and sixth day after plating. All the experiments were per- 
formed at 37°C. 
2.3. lmmunofluorescence labelling of SNAP-25 in intact and 
permeabilized chromaffin cells 
Cultured chromaffin cells were incubated for 90 min with the primary 
anti-SNAP-25 monoclonal ntibody (mAb) (1:250 dilution) in Krebs/ 
HEPES solution containing 1% BSA and then washed 4 times with 
antibody-free solution. Thereafter, cells were fixed for 5 min with 4% 
paraformaldehyde in TBS buffer (50 mM Tris, pH 7.5 with 500 mM 
NaCI 1% BSA). After washing 3times with TBS, cells were incubated 
for 1 h with the secondary antibody, rhodamine-conjugated rabbit 
anti-mouse lgG (1:200 dilution) in 1% BSA in TBS. Cells were washed 
3 times with TBS, mounted with 80% glycerol in TBS, and photo- 
graphed using a Zeiss Axiophot fluorescence microscope. For permea- 
bilized cells immunostaining, cultures were fixed and permeabilized for
15 rain in pure methanol at -20°C and then incubated with the primary 
and secondary antibodies, as described. 
2.4. Determination of catecholamine r lease from detergent- 
permeabilized chromaffin cells 
Secreted [3H]noradrenaline was determined in digitonin-permeabil- 
ized cells as described [20]. Briefly, cells were incubated with [3H]norad- 
renaline (1/tCi/ml) in DMEM during 4 h. Thereafter, monolayers were 
washed 4 times with a Krebs/HEPES basal solution: 15 mM HEPES, 
pH 7.4, with 134 mM NaCI 4.7 mM KC1 1.2 mM KH2PO 4 1.2 mM 
MgC12 2.5 mM CaCI 2 0.56 mM ascorbic acid 11 mM Glucose. Cells 
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were permeabilized using 20 ¢tM digitonin in 20 mM PIPES, pH 6.8 
with 140 mM monosodium glutamate 2 mM MgC12 2 mM Mg-ATP 
5 mM EGTA, for 5 rain, unless otherwise indicated. Permeabilization 
was carried out in the absence or presence ofthe different immunoglob- 
ulins or peptides. Thereafter, media were discarded and cells were 
incubated for 10 additional min in digitonin-free medium in presence 
or absence of additives. Basal or stimulated secretion were measured 
in media containing 5 mM EGTA or 10/IM Ca ~'+, respectively. Media 
were collected and released catecholamines as well as the total cell 
content were determined by liquid scintillation counting. 
2.5. Peptide synthesis and purification 
Peptides were synthesized by t-boc or Fastmoc Fmoc chemistries 
using an Applied Biosystems 431A automated solid-phase peptide syn- 
thesizer, and cleaved as described [21]. Cleaved peptides were purified 
by RP-HPLC on a VydaC C-18 semipreparative column. Samples of 
crude peptide (10-20 mg) dissolved in 0.1% trifluoroacetic a id were 
applied to the column and eluted with a linear gradient of 90% acetoni- 
trile in 0.1% trifluoroacetic a id. Eluted peaks were monitored by ab- 
sorbance measurements a  214 nm, pooled and lyophilized. Peptide 
purity was assesed by RP-HPLC on a VydaC C-18 analytical column. 
3. Results and discussion 
3.1. SNAP-25 is located at the ~ytosolic surface of the 
chromaffin cell plasma membrane 
An anti-SNAP-25 mAb was used to localize SNAP-25 in 
both intact and permeabilized chromaffin cells in culture. Only 
permeabilized cells were immunostained by the antibody, as 
shown by the annular distribution of the fluorescence tag (Fig. 
1A). In contrast, insignificant fluorescence was detected on cells 
labelled prior to fixation and permeabilization (Fig. 1B,C). 
Thus, the epitope recognized by the anti-SNAP-25 antibody, 
which corresponds to a single band of 26 kDa band present in 
adrenomedullary microsomal nd plasma membrane fractions 
(data not shown), appears to be located at the plasma mem- 
brane and oriented to the cytosolic side. 
3.2. The anti-SNAP-25 mAb inhibits Ca2+-evoked 
cateeholamine r lease from chromaffin cells 
Digitonin-permeabilized chromaffin cells, which are exocy- 
tosis competent [22], were used to test the activity of the anti- 
SNAP-25 mAb on catecholamine s cretion. Cells were permea- 
bilized with 20/tM digitonin for different ime periods before 
a 10 ¢tM Ca 2÷ solution was added to trigger catecholamine 
release (Fig. 2A). The antibody produced both time- and dose- 
dependent inhibition of Ca2+-evoked noradrenaline r lease 
(Fig. 2A,B). When cells were permeabilized in presence of Ca 2+ 
(t = 0), the mAb present in the medium caused no effect on the 
stimulated secretion. In contrast, it inhibited Ca2+-dependent 
[3H]noradrenaline release when cells were permeabilized for 
longer periods prior to Ca 2+ triggering (Fig. 2A). A dose-re- 
sponse curve using 5 min permeabilization time is shown in Fig. 
2B. Half-maximal effect was obtained 5/,tg IgG/ml ofmAb (Fig. 
2B), with a maximal inhibition of 60% at 25 ¢tg/ml IgG/ml of 
mAb. Specificity was assessed using mouse IgG which had no 
effect. SNAP-25 is, therefore, involved in Ca2+-dependent x- 
ocytosis in chromaffin cells. 
3.3. A peptide with the sequence of the C-terminal domain of 
SNAP-25 specifically blocks Cae+-dependent 
catecholamine r lease from chromaffin cells 
We used synthetic peptides to probe the role of specific pro- 
tein domains of SNAP-25 in excitation-secretion c upling. Spe- 
cifically, we focused on the carboxy-terminus of SNAP-25 be- 
cause it is a target of clostridial neurotoxins A and E (BoTx A 
and E), known potent inhibitors of exocytosis [2,23,24], and it 
has been shown to interact with synaptobrevin a d syntaxin 
[2,3,10,11,25]. Notably, a 20-mer peptide ncompassing the C- 
terminal region of SNAP-25 (aa 187-206: SNKTRIDEANQ- 
RATKMLGSG), hereinafter denoted as SNAP-25(187-206), 
blocked the Ca2+-evoked catecholamine release from digitonin- 
A II 
g 
Fig. 1. Immunostaining of permeabilized and intact cultured chromaffin cells. (A) Permeabilized cells. Cells were fixed and permeabilized before 
incubation with the anti-SNAP-25 mAb. Scale bar -- 20 gm. (B) Non-permeabilized c lls. Intact cells were incubated with anti-SNAP-25 mAb before 
fixation in 4% paraformaldehyde. Immunolocalization was performed using a rhodamine-conjugated nti-mouse IgG (A and B). (C) Phase contrast 
microscopy of the same field shown in (B). 
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Fig. 2. Anti-SNAP-25 monoclonal ntibody blocks Ca2+-dependent catecholamine r lease from permeabilized chromaffin cells. (A) Time-dependence 
of inhibition. Cultured cells were incubated with [3H]noradrenaline before digitonin-permeabilization for the indicated time periods in the presence 
or absence of anti-SNAP-25 mAb (25 #g IgG/ml). Thereafter, secretion was induced for 10 rain in media containing either 5 mM EGTA or 10 #M 
Ca 2÷ both in the absence or presence of the antibody. (B) Dose-response curve. Increasing amounts of the anti-SNAP-25 mAb were incubated uring 
detergent permeabilization for 5 min. Control denotes the absence of the antibody or the presence of mouse IgG at the indicated concentration. 
Secretion is expressed as net release (difference between stimulated and basal). Data are mean _+ S.E.M. from 4 independent experiments. Statistical 
significance was assessed using the Student's t-test. *P < 0.01 with respect to control. 
permeabilized chromaffin cells (Fig. 3A). At 100/IM, SNAP- 
25(187-206) inhibited 65% of the Ca2+-dependent [3H]noradre- 
naline release, but had minor effects on constitutive exocytosis. 
A control peptide, with the same amino acid composition as 
SNAP-25(187-206) but in random order (Fig. 3A, SNAP- 
25(187--206)RD: TDSSGREMIKANKQLANGTR),  had no ef- 
fect on Ca2+-dependent secretion. Therefore, the inhibitory ef- 
fect of SNAP-25(187-206) is sequence-specific. Shorter pep- 
tides were inactive (Fig. 3A, SNAP-25(195-201 ): ANQRATK), 
suggesting that a minimum peptide length may be neccesary to 
support an active conformation. Furthermore, a peptide mim- 
icking an N-terminal motif presumably involved in the interac- 
tion with the light chain of BoTx A and E [26] (SNAP-25(49-59) 
(aa 49-59: MLDEQGEQLER)) did not affect CaZ+-triggered 
secretion (Fig. 3A). A dose-response curve for the inhibition 
of [3H]noradrenaline release by SNAP-25(187-206) is shown in 
Fig. 3B. The concentration of peptide required to inhibit half 
of the maximal secretion was 20/~M, with maximal inhibition 
of 65% at 100 #M of peptide. 
Taken together, these data indicate that the carboxy-terminal 
domain of SNAP-25 is involved in CaZ+-evoked catecholamine 
release. The inhibition potency of SNAP-25(187 206) is 10-fold 
higher than that reported for peptides mimicking regions of the 
soluble N-ethylmaleimide s nsitive fusion protein attachment 
(SNAP) proteins injected in the giant synapse of the squid axon 
[27], suggesting that SNAP-25 is critical for Ca2+-regulated 
membrane fusion. The partial blockade of Ca2+-evoked secre- 
tion exerted by the SNAP-25(187-206) and the anti-SNAP-25 
mAb resembles that produced by BoTx A in chromaffin and 
pancreatic fl cells [28-30]. Incomplete block of Ca2+-regulated 
exocytosis appears compatible with the occurrence of at least 
two releasable vesicle pools, the docked and primed vesicles 
[2,30,31]. Our observations suggest hat SNAP-25(187-206) 
might interfere with vesicle priming at the plasma membrane. 
Accordingly, the pool of primed vesicles, which would be insen- 
sitive to SNAP-25(187-206), the mAb or of BoTx A, may ac- 
count for the remaining unblocked secretion. 
3.4. The C-terminal domain of SNAP-25 regulates excitation 
secretion coupling in endocrine cells 
Our results provide functional evidence for the presence of 
the SNAP receptor (SNARE) proteins in neuroendocrine c lls 
[17,18,32], which together with action of clostridial neurotoxins 
on secretion [2,12-14], strongly support the hypothesis of a 
common secretory machinery present in neural and neuroendo- 
crine cells consisting of the described SNARE elements of the 
fusion complex [33]. 
A main result of this study is that a 20-mer peptide that 
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Fig. 3. A synthetic peptide representing the C-terminal sequence ofSNAP-25 inhibited Ca2+-regulated exocytosis from permeabilized chromaffin cells. 
Digitonin-permeabilization lasted 5min and [3H]noradrenaline secretion was evoked in the absence (5mM EGTA) or presence ofCa 2+. (A) Inhibition 
of exocytosis i  sequence specific. Shown is the effect on the basal and Ca2+-stimulated r lease of 100 HM of SNAP-25(187-206) (SNKTRIDEA- 
NQRATKMLGSG), SNAP-25(195-201) (ANQRATK), SNAP-25(187-206) RD (TDSSGREMIKANKLANGTR) and SNAP-25(49-59) (MLDEQ- 
GEQLER). (B) Dose-dependent inhibition of Ca2+-evoked secretion by SNAP-25(187-206). [3H]Noradrenaline is expressed asnet release. Data are 
mean + S.E.M. from 4 different experiments performed in triplicate. Statistical significance was assessed using the Student's t-test. *P < 0.01 as 
compared with control in the absence of peptide. 
mimics the carboxy-terminal domain of SNAP-25 effectively 
blocks the Ca2+-dependent release of catecholamines from 
chromaffin cells without affecting the constitutive exocytotic 
pathway. The blocking effect mimics that exerted by the cata- 
lytically-active light chains ofBoTx A and E [12-14], that cleave 
SNAP-25 single sites in the C-terminal domain [23-24]. This 
cleavage is sufficient to disable the fusion process that leads to 
secretion by inhibiting vesicle priming [2,30]. Presumably, the 
C-terminal domain of SNAP-25 is required for the competent 
attachment of the fusion complex to the plasma membrane that 
precedes the fusion event [2,11]. The SNAP-25 C-terminal pep- 
tide effectively produces imilar effects to BoTx A and E and 
conceivably may inhibit vesicle priming. In other words, the 
peptide appears to uncouple xcitation from secretion. We 
therefore propose the term ESUP for the 'excitation-secretion 
uncoupling peptide', It is anticipated that ESUP would block 
the calcium regulated fusion events that lead to neurotransmit- 
ter release in neuronal synapses. The notion embodied in the 
ESUP activity suggests alternative pathways to regulate synap- 
tic vesicle exocytosis and points to previously unrecognized 
means of intervention. 
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